Immunome, Inc. (IMNM) Cash Flow Statement
Immunome, Inc. (IMNM) generated -$208.8M of operating cash flow over the twelve months to 2026-06-30, spent $10.3M on capital expenditure and had free cash flow of -$219.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMNMImmunome, Inc.Follow IMNM — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 22 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -7.6 | -110.8 | -190.9 | -208.8 | |
| Capital expenditure | 0.8 | 7.2 | 9.7 | -10.3 | |
| Free cash flow | -8.4 | -118.0 | -200.6 | -219.1 | |
| Stock-based compensation | 6.2 | 15.7 | 25.7 | — |
USD millions · SEC XBRL
Immunome, Inc. — questions
- What is Immunome, Inc.'s operating cash flow?
- -$208.8M over the twelve months to 2026-06-30.
- How much does Immunome, Inc. spend on capital expenditure?
- $10.3M over the twelve months to 2026-06-30.
- What is Immunome, Inc.'s free cash flow?
- -$219.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Immunome, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.